Objectives . To examine whether postpartum maternal prescription of codeine was associated with an increased risk of harm to newborns. Design . Population-based retrospective cohort study. Setting . Ontario, Canada, from April 1, 1998 to March 1, 2008. Participants . A total of 7804 mothers with publically-funded prescription drug coverage. Women who received a prescription for a codeine-containing product within 7 days following hospital discharge and their neonates were matched to 7804 mothers who did not receive codeine following delivery. Main outcome measures . The primary outcome was readmission of the neonate to hospital for any reason within 30 days. Secondary outcomes included arrival to hospital by ambulance, hospitalization for dehydration, for injury, any hospitalization involving resuscitation or assisted ventilation, and all-cause mortality. Results. We studied 7804 infants whose mothers fi lled a prescription for codeine shortly after delivery and 7804 whose mothers did not. In the primary analysis, infants whose mothers received codeine were no more likely to be readmitted to hospital in the subsequent 30 days than children whose mothers did not (hazard ratio 0.95, 95% confi dence interval (CI) 0.81 -1.11). Moreover, we found no association between maternal codeine use and the other adverse neonatal outcomes studied. A stratifi ed analysis revealed no differential risk among infants born by Caesarian section (hazard ratio 0.86; 95% CI 0.69 -1.08).
Introduction
Codeine is one of the most widely used analgesics in the world, but is a prodrug and must be converted to morphine for effective analgesia. This biotransformation is catalyzed by cytochrome P450 isoenzyme 2D6 (CYP2D6), a highly polymorphic drug metabolizing enzyme, leading to marked inter-individual variability in the amount of morphine produced. 1,2 Approximately 7% of Caucasians display the poor metabolizer (PM) phenotype, lacking functional CYP2D6 activity and deriving minimal analgesia from codeine. 1 Individuals with the intermediate metabolizer (IM) and extensive metabolizer (EM) phenotypes have attenuated and normal enzyme levels, respectively, while those displaying the ultrarapid metabolizer (UM) phenotype have increased enzymatic activity. The prevalence of this phenotype varies widely, ranging approximately from 5.5% of Western Europeans to 30% of persons from Saudi Arabia and Ethiopia. 3 Like nonsteroidal anti-infl ammatory drugs, codeinecontaining medications are commonly used for the treatment of pain following childbirth, particularly following Caesarian section or episiotomy. The majority of new mothers also initiate breastfeeding. 4 Although the use of codeine during breastfeeding has long been considered safe, a recent case report described a neonate whose death on day 13 was attributed to opioid intoxication after the child ' s mother was prescribed acetaminophen with codeine for episiotomy-related pain. 5 The mother was subsequently found to have a CYP2D6 * 2 ϫ 2 gene duplication consistent with UM status. The authors concluded that the mother ' s genotype caused large amounts of morphine to pass into breast milk, causing the child ' s death. 5, 6 However, this conclusion has been challenged on the grounds that even very large amounts of breast milk would not be expected to yield the levels of morphine (70 μ g/L) or acetaminophen (5.9 mg/L) identifi ed on postmortem analysis of the newborn ' s blood. 7 Although this case report and a small retrospective study 8 raised concern about the safety of postpartum codeine use, particularly among mothers exhibiting the CYP2D6 UM phenotype, other evidence suggests that neonates born to mothers with CYP2D6 EM status (a much larger group in most areas of the world) are also at risk for morphine accumulation. 9 In light of the global prevalence of the EM and UM CYP2D6 phenotypes and the widespread use of codeine following delivery, it is likely that many neonates worldwide are exposed to morphine in breast milk each year. However, the potential relationship between maternal use of codeine and adverse neonatal outcomes has to date only been described in case reports and small observational studies. 6,8 -10 Using 10 years of linked healthcare data in a large population, we examined whether postpartum maternal prescription of codeine was associated with an increased risk of death or hospital admission among newborns.
Methods

Study population
We conducted a population-based retrospective cohort study using propensity score matching, an advanced modeling technique that uses a large amount of healthcare data to identify highly comparable groups of patients. 11 The analysis included women living in Ontario, Canada who gave birth in hospital between April 1, 1998 and March 31, 2008 and who, along with their newborn, were discharged within 7 days of delivery. Ontario is Canada ' s most populous province, with an estimated population of 13 million at the end of the study period. We included only singleton deliveries and excluded women younger than 16 years of age at the time of delivery. We limited the analysis to women with available prescription records by excluding all women who did not receive at least one publically-funded prescription within 180 days following hospital discharge. This project was approved by the ethics review board of Sunnybrook Health Sciences Centre, Toronto.
Data sources
We identifi ed prescription records from the Ontario Public Drug Benefi t Program, which contains comprehensive prescription records for all provincial residents younger than 65 years of age receiving social assistance, either by virtue of unemployment or because of high prescription drug costs relative to net household income; this sample represents approximately 5.5% of the total provincial population. We identifi ed deliveries and hospitalizations using the Canadian Institute for Health Information Discharge Abstract Database, which contains detailed diagnostic and procedural information for all hospital admissions. We identifi ed mother -child pairs based upon the mother ' s hospital chart number and, when necessary, by matching according to healthcare facility, discharge date, and home postal code using an algorithm described in detail elsewhere. 12,13 Basic demographic information, including date of death, was identifi ed using the Registered Persons Database, which contains a unique entry for all Ontario residents ever issued a health card. These databases are routinely used to study drug safety 14 -16 and were linked in an anonymous fashion using encrypted 10-digit health-card numbers.
Identifi cation of study subjects
We identifi ed two cohorts of women and their neonates for comparison. The exposed group was defi ned as those women who fi lled a prescription for a codeine-containing analgesic within 7 days following hospital discharge while the unexposed group did not fi ll a codeine prescription during the same interval. For each mother who received a prescription for codeine, one untreated mother was identifi ed using propensity score matching 17,18 an advanced modeling technique that incorporated numerous factors that might infl uence maternal drug exposure or neonatal outcomes (Supplementary Appendix 1 to be found online at http:// www.informahealthcare.com/doi/abs/10.3109/15563650. 2012.681052). Treated and untreated mothers were matched n calendar year of delivery, maternal age (within 3 years), mode of delivery (Caesarian section or vaginal delivery), and propensity score (within 0.2 standard deviations).
We conducted several sensitivity analyses using maternal prescriptions for iron products, nonsteroidal anti-infl ammatory drugs and hemorrhoid preparations, with the rationale that, unlike codeine, maternal prescriptions for these products should have no bearing on neonatal health status. Within the treated group, mothers who received prescription for both a codeine-containing analgesic and a nonsteroidal anti-infl ammatory drug within 7 days of discharge were excluded from the analysis.
Outcomes
All neonates were followed for up to 30 days from the date of the mother ' s codeine prescription (the index date) or, in the case of untreated mother -child pairs, a 30-day period that commenced after the same interval between hospital discharge and maternal codeine prescription for the corresponding exposed mother -child pair.
The primary outcome was defi ned as any readmission of the neonate to hospital within 30 days of the index date. Secondary outcomes (Supplementary Appendix 2 to be found online at http://www.informahealthcare.com/doi/abs/10.3109/ 15563650.2012.681052) included hospital admission for dehydration within 30 days, hospital admission for injury within 30 days, arrival to hospital by ambulance, hospitalization with resuscitation or assisted ventilation, and death from any cause. Only the fi rst occurrence of a study outcome was considered among infants who experienced multiple outcomes over the study period, and children who died during follow-up were censored on the date of death. Finally, we conducted a subgroup analysis according to mode of delivery, with the rationale that women who gave birth by Caesarian section would be more likely to take opioid analgesics following delivery, and likely at higher doses. 19
Statistical analysis
We compared baseline characteristics of mothers treated and not treated with codeine, and their respective infants, using standardized differences, which represent the difference between means divided by the pooled standard deviation. Values less than 0.10 suggest negligible differences between groups. The primary analyses used matched Cox proportional hazards regression, with neonates born to women not prescribed codeine as the reference group. The proportional hazards assumption was verifi ed by testing the statistical signifi cance of a covariate that allowed treatment to have a time-varying effect. All analyses were performed using SAS version 9.2 (SAS Institute, Cary, North Carolina) and used a two-tailed Type 1 error rate of 0.05 as the threshold for statistical signifi cance.
Results
Over the 10-year study period, we identifi ed 7804 mothers who met our criteria and received a prescription for a codeine-containing product within 7 days of hospital discharge. These women were matched to an equal number of mothers who did not receive codeine following delivery, with excellent matching on all measured variables (Table 1) . Infants of mothers prescribed codeine were observed for an average of 28.4 days (standard deviation 3.7 days) while those whose mothers were not prescribed codeine were observed for an average of 28.3 days (standard deviation 3.8 days).
In the primary analysis, 294 (3.8%) children born to mothers who fi lled a prescription for codeine and 312 (4.0%) children whose mothers did not were hospitalized for any reason within 30 days. We found no difference in the risk of readmission within 30 days among children whose mothers were prescribed codeine relative to those whose mothers were not (Table 2 -hazard ratio 0.95; 95% confi dence interval (CI) 0.81 -1.11; Fig. 1) . Similarly, we found no signifi cant difference in risk of neonatal hospitalization for dehydration, injury, arrival to hospital by ambulance, or hospitalization requiring resuscitation or assisted ventilation (Table 3) . We could not draw meaningful inferences regarding neonatal mortality given the infrequent occurrence of neonatal death within 30 days, although the majority of deaths occurred in children whose mothers were not prescribed codeine.
In a subgroup analysis, we found consistent results regardless of whether the child was delivered vaginally (adjusted hazard ratio 1.04; 95% CI 0.83 -1.31) or by Caesarian section (adjusted hazard ratio 0.86; 95% CI 0.69 -1.08) ( Table 2 ). As expected, we found no association between maternal prescriptions for iron, nonsteroidal anti-infl ammatory drugs or hemorrhoid products, and neonatal readmission within 30 days (Table 2 ). Finally, we conducted an additional sensitivity analysis in which observation of all neonates began on the day of hospital discharge. In this analysis, we again found no difference in the risk of hospital admission in the two groups of neonates (hazard ratio 0.98; 95% CI 0.84 -1.14). Finally, we conducted an analysis examining any visit to a physician for any reason within 30 days. In this analysis (which was not prespecifi ed), neonates born to women prescribed codeine post-partum were marginally more likely to see a physician for any reason (hazard ratio 1.09; 95% CI 1.04 -1.13). However, the same was true of children born to women prescribed hemorrhoid therapies after delivery (hazard ratio 1.35; 95% CI 1.00 -1.83). Of note, in both of these analyses, the proportional hazards assumption was not met.
Discussion
Using 10 years of longitudinal healthcare data, we studied nearly 8000 neonates whose mothers were prescribed codeine following delivery, and found that these children were at no greater risk of several adverse health outcomes than children whose mothers were not prescribed codeine.
Importantly, our results should not be construed as an endorsement of codeine therapy, either during breastfeeding or in any other setting. Despite its widespread popularity and familiarity to clinicians, codeine is an inherently irrational analgesic given the unpredictable extent of its conversion to morphine, due to CYP2D6 polymorphisms and interactions with other drugs. 2 In most instances, the administration of a known quantity of codeine amounts to the administration of an unknown quantity of morphine.
Some limitations of our study merit emphasis. First, our analyses derive from women and children receiving social assistance. Whether the results can be generalized to more affl uent populations is not known. Second, we cannot identify nonprescription drug use, including lowdose codeine (8 mg per tablet), which is available without a prescription in Ontario. By design, this is more likely in our unexposed cohort, and would tend to bias our results toward the null, as would use of higher strengths of codeine obtained without a prescription. Third, receipt of a prescription does not necessarily indicate use of a drug; this would lead to an attenuation of our effect estimates. However, a bias of this nature is unlikely to explain our fi ndings, since all of the point estimates in our analyses fall at or below 1.0. Finally, we have no data regarding several important factors including dose and duration of analgesic treatment, ethnicity, CYP2D6 genotype, or breastfeeding status. However, in clinical practice genotype is generally unknown, and would be expected to be distributed evenly among both groups of women in our cohort. Importantly, it has been suggested that neonatal risk is likely only in women who take codeine repeatedly for at least 4 days while breastfeeding, 9 and it is probable that only a minority of women in our study fulfi ll these criteria.
In summary, despite a recent report of neonatal death associated with maternal use of codeine, we found no evidence that prescription of codeine to women following delivery was associated with several measures of neonatal harm in a large population studied over a 10-year period. While these results do not support the prescribing of codeine generally, they do suggest that serious neonatal harm is highly unlikely when the drug is prescribed to women following delivery.
